The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FA | CD20 (Clusters of Differentiation 20) inhibitors | |
| 5 | L01FA01 | Rituximab |
| Active Ingredient | Description | |
|---|---|---|
| Rituximab |
Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BLITZIMA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| REDDITUX Concentrate for solution for infusion | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| RITEMVIA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RITUXAN Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RUXIENCE Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| TRUXIMA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
